Expand all sections

Glycopyrronium

Sialanar

Extended indication Extension of indication to include treatment of children aged from 2 years and older for severe drooling
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Glycopyrronium
Domain Chronic immune diseases
Reason of inclusion Indication extension
Main indication Skin diseases
Extended indication Extension of indication to include treatment of children aged from 2 years and older for severe drooling
Proprietary name Sialanar
Manufacturer Pacira

Registration

Registration route Centralised (EMA)
Submission date February 2024
Expected Registration November 2024
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.